Enrique Grande: A Molecular-Directed Strategy with TP53 Mutation in small cell bladder cancer

Enrique Grande, Head of Oncology at MD Anderson Madrid Cancer Center, recently shared a post on X:

“Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation:

A Molecular-Directed Strategy with TP53 Mutation.”